Syncona Shs GBP (GB:SYNC) has released an update.
Achilles Therapeutics, a Syncona portfolio company, has announced Q1 2024 financial results, revealing a strong cash position of $112.3 million and a net loss decrease from the previous year. The company is advancing its clinical trials in cancer treatment with updated data expected in the second half of 2024, and its cash reserves are expected to fund operations through 2025.
For further insights into GB:SYNC stock, check out TipRanks’ Stock Analysis page.
